Table 1.

Comparison of JAK STAT inhibitors.

JAK-STAT Inhibitor	Target	Type of Application	Phase of Studies	Most Common Side Effects	Dose Related Effect	Tested Dose and Effect on AD
Abrocitinib	Selective JAK1 [36]	Oral	3	Upper respiratory tract infections, headache, nausea, diarrhea	Decrease in platelet count	For 100 mg and 200 mg—achievement EASI-75 and IGA response in week 12.
Baricitinib	Selective JAK1 and JAK2 [37,38]	Oral	3	Nasopharyngitis, headache	None	Improvement in itch was achieved in 1st week for 4 mg and in 2nd for 2 mg, improvements in night-time awakenings, skin pain obtained by 1 st week for both doses.
Upadacitinib	Selective JAK1 [40]	Oral	3	Upper respiratory tract infections	30 mg once daily turned out to be the most effective	Improvement in EASI for doses 7.5 mg, 15 mg, and 30 mg.
Tofacitinib	Nonselective JAK1/3, TYK2, JAK2 [43,44]	Oral and topical	2	No side effects in this phase were observed	None	Improvement in EASI by 1st week for 2% ointment and significant improvement in itch by day two. For 5 mg and 10 mg twice daily p.o. observed reduction of SCORAD by 66.6% and also reduction of pruritus.
Delgocitinib	Nonselective JAK1, JAK2, JAK3, TYK2, [46,47]	Topical	3	Mild white blood cells drop, headache	None	Improvement in EASI for 0.5% ointment.
Ruxolitinib	Selective JAK1 and JAK2 [48]	Topical	2	Pain in the place of application	1.5% cream was the most effective	1.5% RUX cream achieved the greatest improvement in EASI and in IGA. Also rapid itch reduction was obtained.
Cerdulatininb	Selective JAK1, JAK2, JAK3, TYK2, SYK [49]	Topical	2	Diarrhea, neutropenia,	None	0.4% gel has significant EASI improvement. Rapid pruritus NRS score reduction.
Gusacitinib	Selective JAK1, JAK2, JAK3, TYK2, SYK [50]	Oral	1	Headache, nausea, diarrhea, rhino-pharyngitis, back-pain, mild hypertension, decrease in lymphocyte	None	All doses 20 mg, 40 mg and 80 mg were superior to placebo achieving improvement in EASI 50 and 75 with highest efficacy for 40 mg